Nitric Oxide Induces Cardiac Protection by Preventing Extracellular Matrix Degradation through the Complex Caveolin-3/EMMPRIN in Cardiac Myocytes

PLoS One. 2016 Sep 20;11(9):e0162912. doi: 10.1371/journal.pone.0162912. eCollection 2016.

Abstract

Inhibition of Extracellular Matrix degradation by nitric oxide (NO) induces cardiac protection against coronary ischemia/reperfusion (IR). Glycosylation of Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) stimulates enzymatic activation of matrix metalloproteinases (MMPs) in the heart, although the mechanisms leading to EMMPRIN glycosylation are poorly understood. We sought to determine if NO may induce cardiac protection by preventing glycosylation of EMMPRIN in a mouse model of IR. Here we found that Caveolin-3 binds to low glycosylated EMMPRIN (LG-EMMPRIN) in cardiac cells and in the hearts of healthy mice, whereas IR disrupted the complex in nitric oxide synthase 2 (NOS2) knockout (KO) mice. By contrast, the binding was partially restored when mice were fed with an NO donor (DEA-NO) in the drinking water, showing a significant reduction on infarct size (NOS2KO: 34.6±5 vs NOS2KO+DEA-NO: 20.7±9), in expression of matrix metalloproteinases, and cardiac performance was improved (left ventricular ejection fraction (LVEF). NOS2KO: 31±4 vs NOS2KO+DEA-NO: 46±6). The role of Caveolin-3/EMMPRIN in NO-mediated cardiac protection was further assayed in Caveolin-3 KO mice, showing no significant improvement on infarct size (Caveolin-3 KO: 34.8±3 vs Caveolin-3 KO+DEA-NO:33.7±5), or in the expression of MMPs, suggesting that stabilization of the complex Caveolin-3/LG-EMMPRIN may play a significant role in the cardioprotective effect of NO against IR.

MeSH terms

  • Animals
  • Basigin / metabolism*
  • Caveolin 3 / genetics
  • Caveolin 3 / metabolism*
  • Cell Line
  • Extracellular Matrix / drug effects*
  • Extracellular Matrix / metabolism
  • Glycosylation / drug effects
  • Hydrazines / administration & dosage
  • Hydrazines / metabolism
  • Hydrazines / pharmacology
  • Immunoblotting
  • Mice
  • Mice, Knockout
  • Microscopy, Confocal
  • Multiprotein Complexes / metabolism
  • Myocardial Infarction / genetics
  • Myocardial Infarction / metabolism
  • Myocardial Infarction / prevention & control
  • Myocardial Reperfusion Injury / genetics
  • Myocardial Reperfusion Injury / metabolism
  • Myocardial Reperfusion Injury / prevention & control
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Nitric Oxide / metabolism
  • Nitric Oxide Donors / administration & dosage
  • Nitric Oxide Donors / metabolism
  • Nitric Oxide Donors / pharmacology*
  • Nitric Oxide Synthase Type II / genetics
  • Nitric Oxide Synthase Type II / metabolism
  • Protective Agents / administration & dosage
  • Protective Agents / pharmacology

Substances

  • Bsg protein, mouse
  • Caveolin 3
  • Hydrazines
  • Multiprotein Complexes
  • Nitric Oxide Donors
  • Protective Agents
  • Basigin
  • Nitric Oxide
  • 1,1-diethyl-2-hydroxy-2-nitrosohydrazine
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse

Grants and funding

This work was funded by Instituto de Salud Carlos III (Plan Estatal de I+D+i 2013-2016) PI14/02022, and cofinanced by the European Development Regional Fund ‘‘A way to achieve Europe’’ (ERDF), and Ministerio de Economía y Competitividad SAF 2012-35141.